410 related articles for article (PubMed ID: 27285067)
1. Targeting bacterial topoisomerases: how to counter mechanisms of resistance.
Tse-Dinh YC
Future Med Chem; 2016 Jun; 8(10):1085-100. PubMed ID: 27285067
[TBL] [Abstract][Full Text] [Related]
2. DNA Topoisomerases as Targets for Antibacterial Agents.
Hiasa H
Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase as target for antibacterial and anticancer drug discovery.
Kathiravan MK; Khilare MM; Nikoomanesh K; Chothe AS; Jain KS
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):419-35. PubMed ID: 22380774
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Pommier Y; Leo E; Zhang H; Marchand C
Chem Biol; 2010 May; 17(5):421-33. PubMed ID: 20534341
[TBL] [Abstract][Full Text] [Related]
6. Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics.
Tse-Dinh YC
Future Med Chem; 2015; 7(4):459-71. PubMed ID: 25875873
[TBL] [Abstract][Full Text] [Related]
7. Bacterial DNA replication enzymes as targets for antibacterial drug discovery.
Sanyal G; Doig P
Expert Opin Drug Discov; 2012 Apr; 7(4):327-39. PubMed ID: 22458504
[TBL] [Abstract][Full Text] [Related]
8. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
9. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
Kokot M; Anderluh M; Hrast M; Minovski N
J Med Chem; 2022 May; 65(9):6431-6440. PubMed ID: 35503563
[TBL] [Abstract][Full Text] [Related]
10. New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
Badshah SL; Ullah A
Eur J Med Chem; 2018 May; 152():393-400. PubMed ID: 29751233
[TBL] [Abstract][Full Text] [Related]
11. [Bacterial type II topoisomerases as targets for antibacterial drugs].
Pietrusiński M; Staczek P
Postepy Biochem; 2006; 52(3):271-82. PubMed ID: 17201062
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?
Bansal S; Bajaj P; Pandey S; Tandon V
Med Res Rev; 2017 Mar; 37(2):404-438. PubMed ID: 27687257
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
14. Structure activity relationship of substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-4).
Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Meinke PT; Olsen DB; Lagrutta A; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Shibata T; Ohata K; Takano H; Kurasaki H; Takeuchi T; Nishimura A; Fukuda Y
Bioorg Med Chem Lett; 2015 Jun; 25(11):2409-15. PubMed ID: 25911300
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
[TBL] [Abstract][Full Text] [Related]
16. Drugging topoisomerases: lessons and challenges.
Pommier Y
ACS Chem Biol; 2013 Jan; 8(1):82-95. PubMed ID: 23259582
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase inhibition, nucleolytic and electrolytic contribution on DNA binding activity exerted by biological active analogue of coordination compounds.
Patel MN; Bhatt BS; Dosi PA
Appl Biochem Biotechnol; 2012 Apr; 166(8):1949-68. PubMed ID: 22391694
[TBL] [Abstract][Full Text] [Related]
18. Exploitation of a novel allosteric binding region in DNA gyrase and its implications for antibacterial drug discovery.
M Orritt K; Maxwell A; Wg Fishwick C; J McPhillie M
Future Med Chem; 2021 Dec; 13(24):2125-2127. PubMed ID: 34605249
[No Abstract] [Full Text] [Related]
19. Recent advances in bacterial topoisomerase inhibitors.
Bradbury BJ; Pucci MJ
Curr Opin Pharmacol; 2008 Oct; 8(5):574-81. PubMed ID: 18555745
[TBL] [Abstract][Full Text] [Related]
20. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.
Ehmann DE; Lahiri SD
Curr Opin Pharmacol; 2014 Oct; 18():76-83. PubMed ID: 25271174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
